Lyramid is engaged in the research and development of treatments for inflammatory diseases and cancer
targeting midkine, an embryonic growth factor implicated in a number of disease indications. The Company
owns a number of patents pertaining to the use of antibodies against midkine for the treatment of these
conditions. Lyramid holds an exclusive license in relation to these patents.
Rinse and repeat
- Forums
- ASX - By Stock
- AN1
- Is this it?
Is this it?, page-102
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online